Clinical Trials Browser

Phase 2 × Enteropathy-Associated T-Cell Lymphoma × Cyclophosphamide × Clear all

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Withdrawn

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT03113500 2025-11-14

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2 Active not recruiting

48 enrolled 8 charts

LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT06701344 2024-11-22

GOAL

Phase 2 Not yet recruiting

7 enrolled

Lymphoid

Enteropathy-Associated T-Cell Lymphoma

NCT01719835 2018-03-15

CHEMO-T

Phase 2 Unknown

87 enrolled

Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Clinical Trials

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

GOAL

CHEMO-T